Although guidelines (Cusi et al., 2022) have mentioned several complementary diagnostic indicators for NAFLD (ALT, GGT, etc.), there is still a lack of susceptible and specific diagnostic indicators for NAFLD and biomarkers to assess the progression of NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.